secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2022-10-28T23:59:59+00:00
Accession:  0001851734-22-000643
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen shareholders approve reverse stock split authorization up to 1-for-30; bylaw amendment fails
--------------------------------------------------------------------------------

- Proposal 5 passed: 104.2M for, 25.4M against; board may implement reverse split at 1:2 to 1:30 ratio.
- Proposal 6 failed: 65.6M for short of 103.4M majority needed; board cannot unilaterally set director count.
- Reverse split authorization expires October 14, 2023; board may act anytime before then.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000185173422000643/0001851734-22-000643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000185173422000643/vtgn20221028_8k.htm
  HTML page:      https://secwatch.observer/filing/0001851734-22-000643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer